Now, I hate to sound like the accountant in the room, but the regulatory impact statement makes no reference to cost benefit. Let's not beat around the bush: this is going to cost the taxpayer another $50 million or more, and I think they have a reasonable expectation that that's necessary and that that would be money well-spent. We don't have that data, and we're not going to have it by the time the winter is ending, much less when we're going to start administering this. So the most important thing, I think, is whether it's going to be safe, and I don't think there's any reason to believe that a fourth dose will be more harmful than the very incredibly infinitesimally rare complications that we've seen with previous doses. 